Antiphospholipid Syndrome Clinical Trials

21 recruiting

Antiphospholipid Syndrome Trials at a Glance

31 actively recruiting trials for antiphospholipid syndrome are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in New York, Baltimore, and Beijing. Lead sponsors running antiphospholipid syndrome studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China, and Centre Hospitalier Universitaire, Amiens.

Browse antiphospholipid syndrome trials by phase

Treatments under study

About Antiphospholipid Syndrome Clinical Trials

Looking for clinical trials for Antiphospholipid Syndrome? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Antiphospholipid Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Antiphospholipid Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 31 trials

Recruiting

Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

Systemic Lupus ErythematosusAntiphospholipid Syndrome
Hospital for Special Surgery, New York700 enrolled10 locationsNCT00198068
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 2

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

Pregnancy ComplicationsHigh Risk PregnancyAntiphospholipid Syndrome in Pregnancy+1 more
David Ware Branch55 enrolled3 locationsNCT03152058
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting

Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients

ThrombophiliaAntiphospholipid Syndrome (APS)Venous Thrombosis (Disorder)
Infanta Leonor University Hospital600 enrolled2 locationsNCT07372170
Recruiting
Not Applicable

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Systemic Lupus ErythematosusSjogren's SyndromeSystemic Sclerosis (SSc)+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University15 enrolled1 locationNCT06614270
Recruiting

Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study

Antiphospholipid Syndrome
University of California, Davis50 enrolled1 locationNCT00616317
Recruiting

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

Arterial ThrombosisAntiphospholipid Syndrome
McMaster University150 enrolled3 locationsNCT05646394
Recruiting
Not Applicable

Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)

Antiphospholipid Syndrome
CHU de Reims400 enrolled1 locationNCT07163338
Recruiting
Not Applicable

Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome

Antiphospholipid Syndrome
Centre Hospitalier Universitaire, Amiens60 enrolled1 locationNCT06373926
Recruiting

Follow-up Cohort of Patients With Antiphospholipid Syndrome

Antiphospholipid Syndrome (APS)
University Hospital, Rouen200 enrolled1 locationNCT07178925
Recruiting
Phase 1Phase 2

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
Peking University Third Hospital9 enrolled1 locationNCT06828042
Recruiting
Phase 2

Anti-CD38 Antibody Treating APS With Thrombocytopenia

ThrombocytopeniaAntiphospholipid Syndrome
Institute of Hematology & Blood Diseases Hospital, China10 enrolled1 locationNCT05983952
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting

Negative Antiphospholipid Syndrome: a Multicentric Study

Antiphospholipid SyndromeSeronegative Antiphospholipid Syndrome
Italian Society for Rheumatology105 enrolled1 locationNCT06373003